7-Chloro-2-methyl-3,4-dihydro-2H-1,4-benzoxazine | 1173183-85-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 7-Chloro-2-methyl-3,4-dihydro-2H-1,4-benzoxazine
• 英文别名: 7-chloro-2-methyl-3,4-dihydro-2H-1,4-benzoxazine
• CAS: 1173183-85-1
• 化学式: C₉H₁₀ClNO
• 分子量: 183.637
• InChiKey: MNCYCJSKIJWGKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(4-Chloro-2-iodoanilino)propan-2-ol 在 copper(l) iodide 、 1,10-菲罗啉 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 以86%的产率得到7-Chloro-2-methyl-3,4-dihydro-2H-1,4-benzoxazine
  参考文献：
  名称：

  Efficient synthesis of 2,3-dihydro-1,4-benzoxazines via intramolecular copper-catalyzed O-arylation

  摘要：

  A highly efficient synthetic approach to 2,3-dihydro-1,4-benzoxazines is described. The method involves a mild intramolecular copper-catalyzed O-arylation of beta aminoalcohol, which works well without N-protection. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.04.055

文献信息

• [EN] ENZYME INHIBITORS<br/>[FR] INHIBITEURS D'ENZYMES
  申请人：KALVISTA PHARMACEUTICALS LTD

  公开号：WO2021032933A1

  公开（公告）日：2021-02-25

  The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.

  本发明提供了如下式(I)的化合物：化合物组合物；在治疗中使用这些化合物；以及使用这些化合物治疗患者的方法；其中A、Y、n、R1、R2A、R2B、R3和*1如本文所定义。
• [EN] ARYL HYDROCARBON RECEPTOR ACTIVATORS<br/>[FR] ACTIVATEURS DU RÉCEPTEUR D'HYDROCARBURE ARYLE
  申请人：UNIV OREGON STATE

  公开号：WO2021022061A1

  公开（公告）日：2021-02-04

  Small molecule AhR ligands are disclosed. The ligands can induce the differentiation of Tr1 cells to suppress pathogenic immune responses without inducing nonspecific immune suppression. Methods of treatment of autoimmune diseases using the AhR ligands are also disclosed.

  披露了小分子AhR配体。这些配体可以诱导Tr1细胞分化，抑制病原免疫反应，而不引起非特异性免疫抑制。还披露了使用AhR配体治疗自身免疫疾病的方法。
• INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
  申请人：Praxis Biotech LLC

  公开号：US20210317102A1

  公开（公告）日：2021-10-14

  The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
• Efficient synthesis of 2,3-dihydro-1,4-benzoxazines via intramolecular copper-catalyzed O-arylation
  作者：Zhangqin Liu、Yuanwei Chen

  DOI：10.1016/j.tetlet.2009.04.055

  日期：2009.7

  A highly efficient synthetic approach to 2,3-dihydro-1,4-benzoxazines is described. The method involves a mild intramolecular copper-catalyzed O-arylation of beta aminoalcohol, which works well without N-protection. (C) 2009 Elsevier Ltd. All rights reserved.